Investments
267Portfolio Exits
73Funds
6Partners & Customers
1Service Providers
2About Oxford Bioscience Partners
Oxford Bioscience Partners (OBP), established in 1992, is a venture capital firm that provides equity financing and management assistance to emerging, entrepreneurial-driven companies within the life sciences and healthcare sectors. The firm has approximately $1B of committed capital under management.
Oxford Bioscience Partners Headquarter Location
222 Berkeley Street Suite 1650
Boston, Massachusetts, 02116,
United States
Expert Collections containing Oxford Bioscience Partners
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Find Oxford Bioscience Partners in 1 Expert Collection, including Synthetic Biology.
Synthetic Biology
382 items
Latest Oxford Bioscience Partners News
Aug 2, 2017
11/9/2006 10:08:13 AM MALVERN, Pa., Nov. 8 /PRNewswire/ -- Solstice Neurosciences, Inc., a privately held biopharmaceutical company, announced that it has received a combined $85 million in Series B Equity funding and Debt financing.Highland Capital Management, L.P. of Dallas, Texas, led the Series B financing which included participation by existing Series A investors: Thomas, McNerney & Partners, Investor Growth Capital Inc., Morgan Stanley Venture Partners, and Oxford Bioscience Partners. Brett Pope and Nathan Hukill of Highland Capital Management will join Solstice's board of directors with the closing of this financing agreement. These new funds will support the company's ongoing initiatives related to movement disorders and treatment for cervical dystonia using Myobloc® (Botulinum Toxin Type B) Injectable Solution (also sold and distributed as NeuroBloc® in Europe). In addition, the proceeds from this financing will be used to fund growth initiatives and advance product development. "Solstice Neurosciences is excited to receive this new round of financial support from the investors, who recognize the value of Solstice as a growing specialty biopharmaceutical company," said Shawn O'Brien, President and Chief Executive Officer at Solstice. "Solstice is now positioned to expand MYOBLOC sales in this attractive, fast-growing, two-player neurotoxin market." Michael Pagnotta, Chief Financial Officer for Solstice, added, "Having this prominent group of investors committed to both equity funding and debt financing validates our investors' confidence and shared vision in Solstice." Aquilo Partners, Inc., a life science investment bank, was the exclusive placement agent for the equity funding. About Solstice Neurosciences, Inc.: Founded in 2004, Solstice Neurosciences, Inc. is a biopharmaceutical company focused on the development, manufacturing, sales and marketing of specialty products. With headquarters in Malvern, Pennsylvania, Solstice has its manufacturing and customer operations in South San Francisco, California, which is supported by a nationwide sales force. Solstice's first product, Myobloc® (Botulinum Toxin Type B) Injectable Solution 5,000U/mL, represents the only botulinum toxin type B currently available to physicians and patients worldwide. Solstice purchased worldwide rights to MYOBLOC and NeuroBloc from Elan Pharmaceuticals in July 2004. MYOBLOC is sold in the United States and approved in Canada. It is also sold and distributed in 8 markets in Europe as NeuroBloc®. MYOBLOC is indicated for the treatment of patients with cervical dystonia (CD) to reduce the severity of abnormal head position and pain associated with CD. Solstice Neurosciences, Inc. has an agreement with Eisai Co., Ltd. of Tokyo, Japan, to develop and market NerBloc® (MYOBLOC) in Japan. Solstice also recently announced an agreement with DreamPharma Corporation to develop and market MYOBLOC for CD, other therapeutic and cosmetic uses in South Korea. For more information about Solstice Neurosciences, Inc., visit www.solsticeneuro.com. About Highland Capital Management, L.P. Based in Dallas, Texas, with offices in New York and London, Highland Capital Management, L.P. ("Highland Capital") is a SEC-registered investment adviser specializing in credit and alternative investment investing. Highland Capital currently manages over $30 billion in leveraged loans, high yield bonds, structured products and other assets for banks, insurance companies, pension plans, foundations, and high net worth individuals. About Cervical Dystonia Cervical Dystonia (CD), also known as spasmodic torticollis, is a condition that primarily affects the muscles of the head and neck (the cervical area of the spine). Cervical dystonia is the most common dystonia requiring referral to movement disorder clinics. While the exact cause of CD is unknown, scientists believe the problem originates in the basal ganglia area of the brain that is instrumental in movement. Dystonia has an estimated prevalence of over 300,000 cases in North America, of which 50,000 are CD patients. In general, there are three main approaches to the treatment of CD: oral medications, surgery, and neurotoxin therapy. MYOBLOC and NeuroBloc are registered trademarks of Solstice Neurosciences, Inc. NerBloc (the tradename used for MYOBLOC in Japan) is a registered trademark of Eisai Co., Ltd., Tokyo, Japan. Source: Solstice Neurosciences, Inc.
Oxford Bioscience Partners Investments
267 Investments
Oxford Bioscience Partners has made 267 investments. Their latest investment was in QurAlis as part of their Series A on May 5, 2020.
Oxford Bioscience Partners Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
5/13/2020 | Series A | QurAlis | $42M | Yes | 8 | |
8/8/2018 | Series C - II | SQZ Biotech | $72M | Yes | 6 | |
6/16/2015 | Series C | Greenlight Biosciences | $20.01M | Yes | 2 | |
1/6/2015 | Series D - II | |||||
11/13/2014 | Series D |
Date | 5/13/2020 | 8/8/2018 | 6/16/2015 | 1/6/2015 | 11/13/2014 |
---|---|---|---|---|---|
Round | Series A | Series C - II | Series C | Series D - II | Series D |
Company | QurAlis | SQZ Biotech | Greenlight Biosciences | ||
Amount | $42M | $72M | $20.01M | ||
New? | Yes | Yes | Yes | ||
Co-Investors | |||||
Sources | 8 | 6 | 2 |
Oxford Bioscience Partners Portfolio Exits
73 Portfolio Exits
Oxford Bioscience Partners has 73 portfolio exits. Their latest portfolio exit was Greenlight Biosciences on February 03, 2022.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
2/3/2022 | Reverse Merger | 3 | |||
10/30/2020 | IPO | Public | 2 | ||
12/25/2019 | IPO | Public | 5 | ||
Date | 2/3/2022 | 10/30/2020 | 12/25/2019 | ||
---|---|---|---|---|---|
Exit | Reverse Merger | IPO | IPO | ||
Companies | |||||
Valuation | |||||
Acquirer | Public | Public | |||
Sources | 3 | 2 | 5 |
Oxford Bioscience Partners Fund History
6 Fund Histories
Oxford Bioscience Partners has 6 funds, including Oxford Bioscience Partners V LP.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
---|---|---|---|---|---|
10/31/2006 | Oxford Bioscience Partners V LP | Early-Stage Venture Capital | Closed | $148M | 1 |
2/6/2002 | Oxford Bioscience Annex Fund | ||||
10/17/2001 | Oxford Bioscience Partners IV LP | ||||
12/29/1999 | Oxford Bioscience Partners III LP | ||||
4/30/1997 | Oxford Bioscience Partners II LP |
Closing Date | 10/31/2006 | 2/6/2002 | 10/17/2001 | 12/29/1999 | 4/30/1997 |
---|---|---|---|---|---|
Fund | Oxford Bioscience Partners V LP | Oxford Bioscience Annex Fund | Oxford Bioscience Partners IV LP | Oxford Bioscience Partners III LP | Oxford Bioscience Partners II LP |
Fund Type | Early-Stage Venture Capital | ||||
Status | Closed | ||||
Amount | $148M | ||||
Sources | 1 |
Oxford Bioscience Partners Partners & Customers
1 Partners and customers
Oxford Bioscience Partners has 1 strategic partners and customers. Oxford Bioscience Partners recently partnered with Evotec on .
Date | Type | Business Partner | Country | News Snippet | Sources |
---|---|---|---|---|---|
Licensee | Germany | Hamburg , Germany | Oxfordshire , UK | Boston , USA - Evotec OAI -LRB- Deutsche Börse : EVT , TecDAX 30 -RRB- , a leading partner for integrated high-value-added drug discovery and development solutions to the pharmaceutical and biotechnology industries , and Oxford Bioscience Partners , Boston , USA , a premier life-sciences venture capital firm , announced today that they have expanded their 2002 agreement by integrating Evotec OAI 's newly established rational drug design platform , EVOrationale -LRB- TM -RRB- . | 3 |
Date | |
---|---|
Type | Licensee |
Business Partner | |
Country | Germany |
News Snippet | Hamburg , Germany | Oxfordshire , UK | Boston , USA - Evotec OAI -LRB- Deutsche Börse : EVT , TecDAX 30 -RRB- , a leading partner for integrated high-value-added drug discovery and development solutions to the pharmaceutical and biotechnology industries , and Oxford Bioscience Partners , Boston , USA , a premier life-sciences venture capital firm , announced today that they have expanded their 2002 agreement by integrating Evotec OAI 's newly established rational drug design platform , EVOrationale -LRB- TM -RRB- . |
Sources | 3 |
Oxford Bioscience Partners Service Providers
2 Service Providers
Oxford Bioscience Partners has 2 service provider relationships
Service Provider | Associated Rounds | Provider Type | Service Type |
---|---|---|---|
Counsel | |||
Service Provider | ||
---|---|---|
Associated Rounds | ||
Provider Type | Counsel | |
Service Type |
Partnership data by VentureSource
Oxford Bioscience Partners Team
15 Team Members
Oxford Bioscience Partners has 15 team members, including current Chief Financial Officer, Raymond Charest.
Name | Work History | Title | Status |
---|---|---|---|
Raymond Charest | Chief Financial Officer | Current | |
Shari Cohen | Controller | Current | |
Edmund Martin Olivier | General Partner | Current | |
Cornelius T. Ryan | General Partner | Current | |
Alan G. Walton | General Partner | Current |
Name | Raymond Charest | Shari Cohen | Edmund Martin Olivier | Cornelius T. Ryan | Alan G. Walton |
---|---|---|---|---|---|
Work History | |||||
Title | Chief Financial Officer | Controller | General Partner | General Partner | General Partner |
Status | Current | Current | Current | Current | Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.